Radical Life Extension group:
Scientists, analysts and enthusiasts-biohackers

We are solving the practical challenge of radical life extension
And, be honest, we really hope to solve this problem within our own lifetime.
Who are we? Core members of the RLEgroup
Yuri Khait
"Anything less than immortality is a complete waste of time!" (Futurama). Yuri took this joke quite literally and decided that to begin with he had to beat aging first.

IT-entrepreneur, Master's degree in engineering.

About 10 years ago, I got so interested in the question of life extension that it gradually became my top priority in life .

In 2013, my associates and, I created an informal structure, that eventually evolved into the RLEgroup project.

In 2015, I became one of the founders and ideologists of the largest Russian-language network project "Technologies of Longevity", which currently has about 160,000 subscribers.


Alexander Fedintsev
"Every natural science contains as much truth as much mathematics it contains." Alexander agrees with Immanuel Kant and first learned how to evaluate the rate of aging mathematically."

Alexander is a biogerontologist and an expert in machine learning. His scientific background lies in the field of computational biology, statistics, and machine learning.

Alexander worked in the Institute of Antimicrobial Chemotherapy as a bioinformatician. He also collaborated with professor Alexey Moskalev's lab on aging research. After quitting academia, Alexander switched to machine learning engineering however he continued collaborating on aging research with professor Moskalev.

He co-authored the book "Potential geroprotectos" and developed a highly accurate non-invasive biomarker of aging based on markers of the cardiovascular system. His research interest is mainly focused on the role of extracellular matrix (ECM) in the aging process however he also has an expertise in biomarkers of aging and geroprotectors. He and professor Moskalev recently suggested treating non-enzymatic modifications of long-living proteins (mostly, in the ECM) as a 10th hallmark of aging. This paper was mentioned by Fortune in 2020.
Stanislav Polozov
He would invent everything in this world, but now Stanislav is busy solving the problem of how people do not die….

After graduating with a Master's degree in computational biology from Kiev State University, Department of Molecular Biology and Genetics, he worked in the Institute of Molecular Oncology at the Hannover Medical School (MHH), Germany.

At that time he started to make his first engineering inventions (for today he has more than 100 of them), e.g. computer display with subtractive color mixing (patent DE4443470A1), the principle of which is used in the most modern display technologies.

Later he was engaged in several high-tech and scientific projects. While working for the biomedical investment fund "Angelico Ventures", he has provided several major transactions in the biopharmaceutical market.

Another engineering hobby of Stanislav is electric aircraft with vertical takeoff and landing - eVTOL.
Nikolay Sidorov
"The best clinical trial is self-trial. Following this principle, Nikolai has every chance to become the first ageless person on Earth."

Nikolay has a master's degree in psychology from Yaroslavl State University. Being a skilled expert in social psychology, he worked in the highest state bodies of the Russian Federation, ex-vice-governor of the Primorsky Krai of the Russian Federation.

He is a member of the board of the Foundation for Technological Modernization and Development.

Nikolay is an uncompromising researcher of new approaches in anti-aging therapy. He has personally tested almost all available methods of slowing down aging - complete replacement of microbiota, all known senolytics, plasmapheresis and much more.
Dig in further for loads of seriously important info on how we are trying to achieve radical life extension
Our values
A clear goal
Slowing down aging and rolling back aging is the first goal on the road to unlimited longevity. We believe that a total victory over aging is possible.
Science and technology.
We rely only on the achievements of science and technology.

Constant movement
We follow the strategy of small, incremental practical steps in the right direction.

Risk analysis
We analyze all health and longevity risks and do our best to mitigate the most significant ones
We realize that the time is short, and so, we advance towards our goal as quickly as possible
We prioritize things that can be used in the near future
What makes us unique
Our projects cover all the full range of major aging issues: cardiovascular problems, cancer, dementia, metabolic disorders, sarcopenia, and others..
We do not focus on any single cause or pathological process. Aging is a complex, multifaceted phenomenon. It cannot be solved by advancing in one direction only.
Our long-term focus is to investigate the impact of the structural degradation of the extracellular matrix and other long-lived proteins on the organism’s aging. We postulate that these processes can have a bigger impact than other known mechanisms of aging.
Our vision for defeating aging
We believe a total victory over aging is possible. This means:
Risks reduction
Reducing disease and mortality risks to the level of a young person and maintaining this level indefinitely.
Achievement of the functionality of organs and tissues, appearance and general condition up to the age of 25-30 years
Current and long-term health is an inevitable consequence of the cessation of aging processes

But this will not happen soon.

We and our “comrades-in-arms” plainly need to last out to that time.

How can this be achieved?

This is why we have developed our roadmap.

Our roadmap for the next 50 years

Stage 1. Currently being implemented
Not to die from an age-dependent disease, while keeping your body as healthy as possible.
What has already been achieved
a modest impact on life expectancy. The combination of several effective techniques from our near-future portfolio can extend life
Readily available. Healthy lifestyle, dietary supplements, off-label use of well-known drugs and techniques.
To find ways to effectively use existing simple tools and techniques
We already have a lot of practical experience in reducing the risks of age-related diseases.
Stage 2. Next 3-10 years
To ensure access to personalized therapies that can stabilize or minimize the risks of all age-related pathologies, as well as access to relevant biomarkers.
What will be achieved
Development and introduction into the clinical practice of “strong” methods of altering life expectancy. Attaining the largest possible reduction of age-related risks in order to approach maximum life expectancy. This stage does not yet lead to a slowdown in aging or to an increase in maximum life expectancy.
  • gene therapy to rejuvenate blood vessels, heart, kidneys, brain, etc.
  • gene therapy to combat fat accumulation and protect against type 2 diabetes, etc.
  • stem cell pool rejuvenation therapy.
  • therapy to treat sarcopenia
A portfolio of projects for the next 2-3 years has been formed
Stage 3. Next 10-25 years
To influence the basic mechanisms of aging, to stop and rollback aging processes, to increase the maximum life expectancy.
What will be achieved
Real ways of influencing the aging process, showing aging retardation through specific biomarkers.
Complex rejuvenation of extracellular matrix proteins. Restoration of elastin in the extracellular matrix of the skin, blood vessels, lungs, heart and others. Fight against the "cross-linked", old collagen of the extracellular matrix.
The beginning of research on the rejuvenation of extracellular matrix.
Creation of scientific and organizational structures to search for ways to defeat aging and to practically implement those methods.
We develop a research project on the rejuvenation of the extracellular matrix.
We have started the creation of a roadmap for the first phase of research needed to defeat aging and create a “longevity risk management system”.

We are not the greatest experts in packing our extensive anti-aging experience into a nice website, we will get to that later. But we do have a vision for our development and goals

Our current priorities: scientific research, analysis of the current situation in biogerontology and related sciences, experimental proof of hypotheses.


How we achieve goals
We’ve created and regularly update a list of near-term projects for the second and third stages (collecting emerging hypotheses).
We conduct research to test scientific hypotheses and for further patent protection. Funds are being raised for these studies.
We create a scientific structure to conduct research work. Also look for new contract laboratories and researchers.
We form Advisory & Science Boards of high quality professionals.
We develop a staff training system to work in our scientific and commercial structures.
Constantly and consistently expand the field of scientific and analytical research.

We’ve founded our project in 2015,

and this is what we have achieved in the past 6 years:

Milestones of the RLE group
Spring 2015: the first fact sheets of the effectiveness of lifestyle factors and geroprotectors
Summer 2015: the first fact sheets of the effectiveness of lifestyle factors and geroprotectors
Autumn 2015: creation of the info-project "Technologies of Longevity" with the aim to promote the ideas of RLE to a wide audience. At present, the project continues to be successfully developed by a group of interested parties.
Spring 2016: creation of the analytical group to collect the latest research results around the world.
Spring 2016: getting the first successful practical result. The first clinical trial of the combination of "sartans + statins" and instrumental confirmation of atherosclerosis reduction. By now, the protocol is essentially improved. In 2021, this protocol was officially adopted by the Russian Society of Cardiology.
2017: the audience of the project reached 200,000 people
2018: creation of the scientific group to test the latest research results collected around the world.
2019: First meetup of project members in Spain. International status of the project.
2020: Completion of a portfolio of pilot projects, which implementation will help to significantly affect life expectancy, both through reducing the risks of age-related diseases (cardiovascular diseases, cancer, dementia, metabolic disorders, etc.), and through the basic mechanisms of aging.
Spring 2020: the first practical biological experiment, the launch of the first stage of a project to create an antiaging gene therapy.
Autumn 2020: the practical experiment with plasmapheresis according to Irina Konboy's protocol. And than in Summer 2021, start of official clinical trials in plasmapheresis under the scientific supervision of Prof. A. Moskalev.
2021: continuation of the series of experiments to create antiaging gene therapy, an experiment on epigenetic rejuvenation of hematopoietic stem cells

The scientific audience likes the Hirsch index,

so from time to time,

Alexander Fedintsev publishes some of the results of his research.

Scientific publications in the field of biogerontology co-authored by Alexander Fedintsev:
Moskalev, A., Chernyagina, E., Tsvetkov, V., Fedintsev, A., Shaposhnikov, M., Krut'ko, V., ... & Kennedy, B. K. (2016). Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging cell, 15(3), 407-415.
Moskalev, A., Shaposhnikov, M., Proshkina, E., Belyi, A., Fedintsev, A., Zhikrivetskaya, S., ... & Kudryavtseva, A. (2016). The influence of pro-longevity gene Gclc overexpression on the age-dependent changes in Drosophila transcriptome and biological functions. BMC genomics, 17(14), 273-289

Fedintsev, A., Kashtanova, D., Tkacheva, O., Strazhesko, I., Kudryavtseva, A., Baranova, A., & Moskalev, A. (2017). Markers of arterial health could serve as accurate non-invasive predictors of human biological and chronological age. Aging (Albany NY), 9(4), 1280.
Solovev, I., Shegoleva, E., Fedintsev, A. et al. (2019) Circadian clock genes’ overexpression in Drosophila alters diet impact on lifespan. Biogerontology 20, 159–170.
Belyi, A.A.; Alekseev, A.A.; Fedintsev, A.Y.; Balybin, S.N.; Proshkina, E.N.; Shaposhnikov, M.V.; Moskalev, A.A. (2020) The Resistance of Drosophila melanogaster to Oxidative, Genotoxic, Proteotoxic, Osmotic Stress, Infection, and Starvation Depends on Age According to the Stress Factor. Antioxidants 2020, 9, 1239
Fedintsev, A., & Moskalev, A. (2020). Stochastic non-enzymatic modification of long-lived macromolecules-A missing hallmark of aging. Ageing Research Reviews, 62, 101097
Media coverage:
A recent article in “Fortune” magazine about the prospects for overcoming aging fortune.com/2020/12/30/anti-aging-research-health-care-spending-biden refers, among others, to the work of our group member A.Fedintsev, where one of the main causes of aging is damage to long-lived proteins of the extracellular matrix.
About our experiment: Biohackers Perform First Plasma Dilution Experiment on Humans (Lifespan.io)
The main idea is:
"Without us you will definitely die!
And with us you have a chance ..."

(A. Fedintsev)

To move faster and more effectively towards our goal, we organize thematic events or participate in such events as

The following persons are involved in the project alongside us:
Advisory board:
Andrey Isaev
Founder and CEO one of the largest Russian commercial laboratory network “DNKOM” and the network of medical centers “Medgorod”. Pediatrician, graduated from the Russian State Medical University in 2006. He worked in the department of infectious diseases in Moscow Morozov Children's Hospital. After that he was the head of the commercial division of the Central Research Institute of Epidemiology. In 2009 he organized his own project.
He is the author of a number of scientific and medical studies, including the first in Russia study of the dynamics of the development of the immune response in patients with Covid-19. Research interests - anti-age medicine, anti-aging.
Evgeny Kovalev
A psychiatrist, practitioner of preventive and anti-aging medicine. He has deep versatile knowledge in classical medicine and extensive experience in managing patients with chronic diseases. Graduated from the Russian State Medical University in 2004. At the same time he collaborated with several medical publications in editorial positions. Worked as deputy chief physician at Children's Clinical Hospital 38 in Moscow, then moved to the Ministry of Health of the Russian Federation, the Federal Medical Biological Agency. In 2013 he became co-founder and chief physician of a private clinic. In recent years has held executive positions in the medical cluster of the insurance company Sogaz. Additional education - psychiatry, MBA, public administration and others.
Professional scientific interests include molecular mechanisms of life extension, expertise and consulting in biohacking, development of new treatment regimens for mental disorders and substance abuse, food addictions.
Science board:
Alexey Moskalev
Russian scientist-biogerontologist, specialist in the field of genetics of longevity and aging, studies the mechanisms of regulation of the rate of aging and longevity. Doctor of Biological Sciences, Professor, Professor of the Russian Academy of Sciences, Corresponding Member of the Russian Academy of Sciences.
Graduated from Syktyvkar State University. He works at the Institute of Biology of the Ural Branch of the Russian Academy of Sciences, the Gerontological Research and Clinical Center and the Institute of Molecular Biology named after V.I. V.A. Engelhardt. He headed the department at Syktyvkar State University, headed the laboratory of genetics of life expectancy and aging at the Moscow Institute of Physics and Technology. In 2016 he was elected a corresponding member of the Russian Academy of Sciences. Vice-President of the Gerontological Society at the Russian Academy of Sciences, member of the Central Council of the Vavilov Society of Geneticists and Breeders.
Author of many scientific and popular science books on longevity and aging, and many scientific articles in the field of aging genetics, life span genetics and radiation genetics.
Member of the editorial boards of scientific journals: Aging Research Reviews, Biogerontology, Aging, Frontiers in Genetics, Gerontology, Aging and disease, Stem Cell Reviews and Reports, Advances in Gerontology and others.
Since 2008, he has been organizing the annual international conference on aging and longevity.
Leon Peshkin
Lecturer in the Department of Systems Biology at Harvard Medical School, also part of the Marine Biological Laboratory. He holds a PhD in Artificial Intelligence from Brown University and an MA in Applied Mathematics from the Weizmann Institute of Science. Current research interests include embryology, evolution and aging. Leon's research on aging and personal history was highlighted in a recent Boston Globe article. His personal genome is used as the human genome standard by the US National Standards Institute in the Genome in a Bottle program, as described in an article in the journal Genome. Leon's research on the use of artificial intelligence in the biology of aging was highlighted in an interview with the Life Extension Advocacy Foundation and Longevity Technology.
We are looking for like-minded partners who, like us, would rather not die.
If you have made it to this point
and also:
Want to extend your life and the lives of your loved ones as soon as possible
Want to contribute to the victory over aging
Personally motivated to defeat aging using scientific technology
Focused on practical results (increasing life expectancy and improving its quality), rather than quick profits
Appreciate the openness and transparency of cooperation
Inquisitive, ready to learn, to understand new things for yourself
Ready to become a member of our community
Then look what kind of partners we look for
Financial partners, investors.

This collaboration involves the following participation:

In the non-commercial part of the project - through an non-profit organization:

  • creation and maintenance of the work of a non-profit organization,
  • financing of the scientific work,
  • translation of articles into other languages
  • registration of IP (patents, etc)

In the commercial part:

  • Partners in this part are essentially "business angels" who fund projects at a very early, pre-clinical stage.
  • Equity-based commercial startups.
  • We are also ready to discuss strategic partnerships on an individual basis, taking into account your interests and goals.

If you would like to offer a financial cooperation - please contact us: we@rlegroup.net

Coauthors of biomedical experiments.

Managers and employees of scientific labs, preferably in the fields of molecular biology and biochemistry..

Terms of cooperation:

  • on a paid basis from our side
  • with the potential to publish and participate in the formation of intellectual property

We are interested in any opportunities of cooperation with labs. Therefore, if our values are close to you, but you do not yet know exactly what you would like to offer, contact us anyway. We will consider any possible ways of cooperation, including non-public ones: we@rlegroup.net

For all participants in our project we:

  • we provide access to classified information about our current activities, plans, results, biohacker protocols, etc
  • we give the opportunity to receive services at cost price.
  • financial partners have a priority right to participate in investing of commercial projects.
We provide information on specific projects currently underway on request.

If you know someone who might be interested in partnering with us, please let them know about our project.

We are always glad to cooperation and open to communication

You can read our reviews here (only russian)
Made on